Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 8, 2005, Pages 4688-4693

  Wu, Guojun ^a   Mambo, Elizabeth ^a   Guo, Zhongmin ^a   Hu, Shuiying ^a   Huang, Xin ^b   Gollin, Susanne M ^c   Trink, Barry ^a   Ladenson, Paul W ^a   Sidransky, David ^a   Xing, Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110A; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; BENIGN TUMOR; CANCER GENETICS; CATALYSIS; CONTROLLED STUDY; DNA ISOLATION; DNA SEQUENCE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR CARCINOMA; GENE ACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GENE NUMBER; GENETIC ASSOCIATION; GENETIC CODE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLARY CARCINOMA; ONCOGENE; PIK3CA GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID ADENOMA; THYROID CARCINOMA; THYROID TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION, MISSENSE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 23844446683     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-2281     Document Type: Article

References (26)

1. Brader S, Eccles SA 2004 Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90:2-8
2. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M 2004 PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE 2004 High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554
4. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH 2004 The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3:772-775
5. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW 1999 PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102
6. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY 2000 PIK3CA as an oncogene in cervical cancer. Oncogene 19:2739-2744
7. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW 2002 Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62:3636-3640
8. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, Stahl U 2002 Genomic gain of PIK3CA and increased expression of p110α are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198:335-342
9. Miller CT, Moy JR, Lin L, Schipper M, Normolle D, Brenner DE, Iannettoni MD, Orringer MB, Beer DG 2003 Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res 9:4819-4825
10. Byun DS, Cho K, Ryu BK, Lee MG, Park JI, Chae KS, Kim HJ, Chi SG 2003 Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int J Cancer 104:318-327
11. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Over-expression and over-activation of Akt in thyroid carcinoma. Cancer Res 61:6105-6111
12. Miyakawa M, Tsushima T, Murakami H, Wakai K, Isozaki O, Takano K 2003 Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 50:77-83
13. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, Miyakawa M, Isozaki O, Murakami H, Tsushima T, Burman KD, De Micco C, Ringel MD 2004 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41:161-170
14. Kada F, Saji M, Ringel MD 2004 Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metab Disord 4:181-185
15. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67
16. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368
17. Mambo E, Gao X, Cohen Y, Guo Z, Talalay P, Sidransky D 2003 Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proc Natl Acad Sci USA 100:1838-1843
18. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C 2003 Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88:2745-2752
19. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
20. Xing M 2005 BRAF mutations in thyroid cancer. Endocr Relat Cancer 12:245-262
21. Nikiforov YE 2002 RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16
22. Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M 2003 RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17:1382-1394
23. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, Saji M, Ringel MD 2004 Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41:98-107
24. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ 2000 Understanding Ras: "it ain't over 'til it's over." Trends Cell Biol 10:147-154
25. Cheng G, Meinkoth JL 2001 Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene 20:7334-7341
26. Gire V, Marshall C, Wynford-Thomas D 2000 PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19:2269-2276